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Abstract 
Type IV phosphodiesterases (PDE IV) specifically hydrolyze cAMP and are inhibited by rolipram. RT-PCR was applied to analyze the expression 
patterns of mRNAs for four cloned human and rat phosphodiesterase type IV isogenes (PDE IV-A, -B, -C and -D). Although these patterns were 
mostly coincident for the human and rat PDE IV genes, some differences were found between the two species. PDE IV-A expression was detectable 
in human blood but not in rat blood, suggesting a species-specific difference in the expression of this PDE IV isogene. PDE IV-C was neither detected 
in human or rat blood nor in different cell populations of the human immune system. It is further demonstrated that the PDE IV isogene xpression 
is differentially regulated by cAMP in different cell types. 
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1. Introduction 
Cyclic nucleotide phosphodiesterases (PDEs) are in- 
volved in the regulation of cellular processes by modulat- 
ing intracellular cyclic nucleotide l vels. The superfamily 
of phosphodiesterases can be divided into eight types or 
subfamilies [1-3]. They are characterized by their sub- 
strate affinities and specificities or by particular inhib- 
itors [2,4,5]. The subfamilies are Ca2+/Calmodulin-de - 
pendent PDEs (PDE I), cGMP-stimulated PDEs (PDE 
II), cGMP-inhibited PDEs (PDE III), cAMP-specific 
PDEs (PDE IV), cGMP-specific PDEs (PDE V), a pho- 
toreceptor PDE (PDE VI), a high affinity cAMP-specific 
PDE (PDE VII), and a PDE with similar K m values for 
cAMP and cGMP (PDE VIII). In addition, multiple 
related genes as well as different mRNA splice forms 
create various isozymes within these subfamilies [1,6-10]. 
We have focused on the cAMP-specific phosphodi- 
esterase subfamily (PDE IV). Recently, four rat and four 
human cDNA isoforms of this subtype were identified 
[6,11-14]. They are characterized by their selective 1ow- 
Km hydrolysis of cAMP and their sensitivity to rolipram 
and Ro20-1724 [1,4]. As for other PDE-types different 
splice variants have been described for most of the 
cloned PDE IV isoforms [6,7,11,13,14]. 
The existence of a large number of PDE isozymes 
suggests a specific involvement in multiple mechanisms 
governing the regulation of cAMP levels. PDE IV en- 
zymes are of particular interest because they have been 
demonstrated to be involved in the regulation of proc- 
esses like learning and memory [15,16], cell survival [17], 
and activation of the immune response [18]. Increased 
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levels of PDE IV were found in monocytes ofindividuals 
with atopic dermatitis [19]. 
PDE IV activity can be regulated by cAMP analogues, 
agents that increase intracellular cAMP levels or 
hormones uch as follicle-stimulating hormone (FSH) 
[20-23]. Here, we present the results of an extensive RT- 
PCR analysis comparing human and rat PDE IV isogene 
expression i various tissues. The results of the distribu- 
tion analysis revealed a differential expression pattern of 
three isogenes and the absence of one isoform in cells of 
the immune system. Additionally, the influence of cAMP 
on PDE IV mRNA expression was determined in three 
different human cell types. PDE IV-A,-B and PDE IV-D, 
but not PDE IV-C expression was differentially stimu- 
lated by cAMP in cells of the immune system. Interest- 
ingly, a similar regulation was not apparent in the neu- 
ronal cell line analyzed. 
2. Material and methods 
2.1. Oligonucleotides 
PE2h 5'-TCAGAGCTGGCGCTTATGTAC-3'; PE32: 5'-CCGTA- 
TGCTTGTCACACAT-3"; hB1: 5'-AGCGGTGGTAGCGGTGA- 
CTC-3'; hB2-60h 5'-GCTGCGTGCAGGCTGTTGTG-3'; hDl: 5'- 
GCAAGATCGAGCACCTAGCA-3", hD2: 5'-ACCAGACAACTCT- 
GCTATTC-3'; rAl: 5"-GCGGCAAGAGCCTGCGCAAG-3"; rA2: 5"- 
ATGCCAGAGCTCAAGCTGT-3'; rBl: 5'-TCTCAGAGATGAGC- 
AGATCA-3'; rB2~01: 5'-GCTGCGTGCAGGCTGTTGTG-3'; rCh 
5'-CTGCGGAAGTCTTGCCACAC-3'; rC2: 5'-AGACTCAGTTTC- 
TGCTTGG-3'; rDl: 5"-CTGTCTCTTCGCAGAGGAGG-3'; rD2: 5'- 
GTGCATGATAACAGTCAGAGGC-3"; fl-actin-5': 5'-ATGGATG- 
ATGATATCGCCGCG-3'; fl-actin-3': 5'-GATCATGGCTGGGGT- 
GTTGAA-3'. 
2.2. RNA Isolation and RT-PCR 
mRNA from different rat tissues was isolated using the guanidinium/ 
acid phenol method [24] with 1 ml homogenization buffer per 100 mg 
of tissue. Human mRNA was obtained from Clontech. All human 
tumor cell lines used for RT-PCR analysis are available from the Amer- 
ican Type Culture Collection (Rockville, MD). To reduce contamina- 
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tion by genomic DNA, 20 pg RNA were treated for 15 min at 37°C with 
10 units DNase I (RNase free, Boehringer Mannheim), followed by 
phenol/chloroform extraction and ethanol precipitation. Reverse tran- 
scription was performed with M-MLV reverse transcriptase (BRL) in 
PCR buffer. PCR reactions were performed with Taq DNA polymerase 
under the conditions recommended by the manufacturer (Boehringer 
Mannheim). For all four rat and human PDE IV isogenes, specific 
primers were designed and used under similar cycle conditions with 0.2 
,uCi [32p]dCTP added to each reaction (34 cycles: 30 s at 95°C, 30 s at 
55°C, 60 s at 72°C; rat PCR primers: rAl/rA2 for rPDE IV-A, rBl/rB2 
for rPDE IV-B, rCl/rC2 for rPDE IV-C, and rDl/rD2 for rPDE IV-D; 
human PCR primers: PE21/PE32 for hPDE IV-A and -C, hBl/hB2 for 
hPDE IV-B, and hD1/hD2 for hPDE IV-D). Restriction of the PE21/ 
PE32-derived PCR fragments either with BstX1 (hPDE IV-A specific) 
or EcoRV (hPDE IV-C specific) allowed the two different human 
isogenes to be distinguished. After electrophoretic separation of PCR 
products on 4% agarose gels (NuSieve Agarose, FMC), the gels were 
dried and exposed to X-ray film (Amersham) for 1 h. The expected sizes 
of the PCR fragments corresponding tothe different rat isoforms were: 
PDEIV-A = 654 bp, rPDEIV-B = 470 bp, rPDEIV-C = 584 bp and 
rPDEIV-D = 492 bp. For the human isoforms hPDEIV-A and -C a 440 
bp fragment was predicted which could then be digested either with 
BstXI (hPDEIV-A 330 bp + 110 bp fragments) or with EeoRV 
(hPDEIV-C 345 bp + 95 bp fragments) as mentioned above. PCR with 
hPDEIV-B specific primers resulted in a 680 bp band and with 
hPDE1V-D specific primers in a 495 bp fragment. 
Semi-quantitative PCR was performed under the same conditions. 
fl-actin specific primers were used as internal standard. To avoid errors, 
10 pl aliquots were taken after 25, 28, 31 and 34 amplification cycles. 
Radioactivity incorporated into the PCR-products was quantified by 
phosphorimaging (Molecular Dynamics) after electrophoretic separa- 
tion. Because of the sensitivity of competitive RT-PCR experiments o
amplification efficiency, we did not calculate absolute values of tran- 
scriptional induction. 
2.3. Tissue culture 
Human neuroblastoma SH-SY5Y cells were cultivated in DMEM 
with 10% FCS, the human acute leukemia T-cell line (Jurkat JKE6 1) 
in RPME-1640, 10% FCS and 0.1 mM fl-mercaptoethanol. The same 
medium without fl-mercaptoethanol was used for human histiocytic 
lymphoma cells (U937). 
For PDE IV induction studies, 0.5× 10 -3 M dibutyryl-cAMP 
(dbcAMP; Sigma) was added to the medium 18 h before harvesting. 
2 3 × 10 6 cells were used for each experiment. Prior to RNA purifica- 
tion the cells were washed with 1 x PBS. 
3. Results 
3.1. Distribution of human PDE IV isogenes 
(hPDE IV-A, -B, -C, and -D) 
Tota l  mRNA f rom var ious  tissues and cell l ines was 
reverse t ranscr ibed into cDNA.  The express ion patterns 
o f  the four  known human PDE IV isogenes were deter- 
mined by PCR with isogene-specif ic pr imers.  In most  o f  
the human tissues tested, all four  isoforms,  PDE IV-A,  
-B, -C, and -D, were detectable as summar ized  in Table 
1. Examples  o f  the PCR exper iments  are shown in Fig. 
1. No  express ion o f  PDE IV-C was found  in b lood.  In 
addit ion,  we analyzed several def ined cell l ines (e.g. SK-  
N -SH,  SH-SY5Y  neurona l  l ike cells, Ju rkat  acute T cell 
leukemia,  U937 hist iocyt ic l ymphoma promonocyte -  
like) as well as di f ferent puri f ied b lood  cell popu la t ions  
(eosinophi ls ,  neutrophi ls) .  PDE IV-A PCR products  
were der ived in high amounts  f rom all ceils with the 
except ion o f  neutrophi ls .  In Ju rkat  T-cells, PDE IV-A 
was the only detectable isoform. 
PDE IV-B was found  in all t issues and most  o f  the cell 
l ines analyzed with the except ion o f  Ju rkat  cells where 
no PCR product  was found.  In contrast ,  PDE IV-B 
seems to be the dominant  PDE IV isogene in neutrophi ls .  
No  PDE IV-C mRNA was found in any o f  the immune 
system cell types tested. PDE IV-D was also not  detecta-  
ble in Ju rkat  T-cells or  Namalwa B-cells, whi le only very 
weak PDE IV-D express ion was observed in neutrophi ls .  
3.2. Distribution of rat PDE IV isogenes 
(rPDE IV-A,-B, -C, and -D) 
Dif ferent  rat tissues were analyzed by RT-PCR with 
rat PDE IV isogene-specif ic pr imers.  PCR results are 
summar ized  in Table 2 and some examples  are shown in 
hPDEIV-A hPDEIV-B 
1 2 3 41  2 34  
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Fig. 1. Distribution of human PDE IV isoforms analyzed by RT-PCR. Human PDE IV isogene specific primers were used for the PCR analysis. 
hPDE IV-A and -C are recognized by the same PCR primers which give rise a 440 bp product. These two isoforms are then distinguished by digestion 
with BSTXI (hPDE IV-A) or EeoRV (hPDE IV-C) resulting in bands of 330 bp and 110 bp for type A and 345 bp and 95 bp for type C, respectively, 
as indicated by the arrows. The expected size of PCR fragments for hPDEIV-B was 680 bp and for hPDEIV-D 495 bp. 1, T-cells; 2, blood; 3, brain; 
4, kidney. 
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Table 1 
Summary of the RT-PCR results with different human tissues and 
defined cell populations 
hPDE- hPDE- hPDE- hPDE- 
IV-A IV-B 1V-C IV-D 
Brain ++ ++ ++ ++ 
Liver ++ ++ ++ ++ 
Lung ++ ++ ++ ++ 
Trachea + + + + + + + + 
Kidney ++ ++ ++ ++ 
Placenta ++ + + + + + + 
Heart ++ ++ ++ ++ 
Blood ++ ++ - ++ 
Promonocyte likC ++ ++ - ++ 
T like cells 2 ++ - 
B like cells 3 ++ ++ 
Promyelocytic cells 4 ++ ++ - 
Neutrophils + ++ - + 
Eosinophils ++ ++ ++ 
SH-SY5Y 5 ++ ++ ++ ++ 
SK-N-SH 5 ++ ++ + ++ 
++, expression; +, very weak expression; - ,  no expression; 1, U937 
cells; 2, Jurkat cells; 3, Namalwa cells; 4, peripheral blood promyelo- 
cytic HL-60 cells; 5, Neuroblastoma cells. 
Fig. 2. Most  o f  the tissues also expressed rPDE IV-A. 
Interest ingly,  no rPDE IV-A RNA was detected by RT- 
PCR in b lood.  Rat  PDE IV-B and -D were observed in 
all ana lyzed tissues, rPDE IV-C express ion was detected 
in most  t issues with the notab le  except ion o f  b lood.  On ly  
marg ina l  express ion was found  in lung and bra in  
(Table 2). 
3.3. cAMP dependent stimulation o f  human PDE IV  
We tested the inf luence o f  cAMP on the express ion 
levels o f  di f ferent human PDE IV isogenes. Two cell l ines 
der ived f rom the immune system (U937, Jurkat )  and one 
neurona l  cell type (SH-SY5Y)  were used. The  cells were 
incubated for  18 h wi th  0.5 mM dbcAMP before RNA 
was extracted.  To detect increased amounts  o f  PDE IV 
mRNA after  dbcAMP- t reatment ,  a semi -quant i tat ive  
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Fig. 2. Distribution of rat PDE IV isoforms analyzed by RT-PCR with 
rat PDE IV isogene-specific primers. The sizes of the PCR fragments 
were: rPDEIV-A 654 bp, rPDEIV-B 470 bp, rPDEIV-C 584 bp and 
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Fig. 3. Semi-quantitative RT-PCR analysis of PDE IV induction by 
cAMP. RT-PCR was performed with RNAs isolated from U937 cells 
treated with cAMP and controls, hPDE IV isogenes were recognized 
by isogene-specific primers and fl-actin was used as standard. - ,  un- 
treated; +, treated; A, hPDE IV-A; B, hPDE IV-B; D, hPDE IV-D; fl, 
fl-actin; D+fl, mixture of fl-actin and hPDE IV-D specific primers for 
competitive PCR. 
ard. It has prev ious ly  been shown that the express ion o f  
f l -act in is not  modu la ted  by cAMP [13]. The results o f  
exper iments  with unt reated  and treated cells are summa-  
rized in Table 3. PCR exper iments  per fo rmed with U937 
cell RNA are shown in Fig. 3 as an example.  In  U937 
promonocytes ,  which express hPDE IV-A, -B and -D,  we 
observed a more  than 2-fold increase in hPDE IV-A and 
hPDE IV-B express ion whi le no increase was measured  
for  hPDE IV-D (Table 3). Ju rkat  cells express only  
hPDE IV-A. These cells showed an approx imate ly  2-fold 
increase in the PDE IV-A t ranscr ipt  after t reatment  wi th 
cAMP.  Interestingly,  we found transcr ipts  o f  hPDE IV- 
D in s t imulated Ju rkat  T-cells but  not  in unst imulated 
cells. In contrast ,  SH-SY5Y  cells express all four  
i so forms o f  PDE IV. However ,  we cou ld  not  detect a 
s t imulatory  effect o f  cAMP on the t ranscr ipt ion  o f  any 
o f  these genes. 
4. Discussion 
Type IV phosphod iesterases  (PDE IV) are invo lved in 
the modu la t ion  o f  cel lular processes via degradat ion  o f  
the second messenger  cAMP.  Four  di f ferent rat and 
human PDE IV isogenes have been c loned and charac-  
Table 2 
Summary of the RT-PCR results with different rat tissues 
rPDE IV-A rPDE IV-B rPDE IV-C rPDE IV-D 
Brain ++ ++ + ++ 
Liver ++ ++ ++ ++ 
Lung ++ ++ + ++ 
Kidney ++ ++ ++ ++ 
Heart ++ ++ ++ ++ 
Blood ++ - ++ 
++, Expression; +, very weak expression; , no expression. 
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Table 3 
Regulation of hPDE IV isogene xpression i  three different cell lines 
hPDE 1V-A hPDE IV-B hPDE IV-C hPDE 1V-D 
SH-SY5Y - - 
Jurkat + - ++ 
U937 ++ ++ 
Using RT-PCR we analyzed the regulation of PDE IV subtype xpres- 
sion in one neuronal and two immune system derived cell lines after 
treatment with 0.5 x 10 -3 M dbcAMP for 18 h. -, No increase of 
mRNA; +, ~2-fold increase; ++, >2-fold increase. 
terized [6,11-14]. All of these isoforms show a high 
amino acid homology in the catalytic domain but less at 
the N- and C-terminal sequences. Comparison of the 
human and rat amino acid sequences led to the recent 
analogous nomenclature (human PDE IV-A to -D = rat 
PDE IV-A to -D) although only rat and human PDE 
IV-B show a very high homology of 92% over the total 
sequences [14]. For the other three PDE IV isogenes the 
homology is less pronounced. 
Our extensive distribution analysis showed that the 
four isogenes are expressed in most of the human and rat 
tissues tested. This overlapping expression pattern of 
whole organ mRNA may not reflect the real situation 
since the isoforms may be differentially expressed in indi- 
vidual cell types [6,10]. Nevertheless, in human and rat 
blood we found no or only marginal expression of PDE 
IV-C, suggesting that the isoform plays a minor role in 
cAMP regulation in blood cells. In contrast o the RNA 
blotting experiments of McLaughlin et al. [25] we de- 
tected transcripts of hPDE IV-B in liver and kidney. 
These results may be due to the higher sensitivity of 
RT-PCR versus Northern blotting, although we cannot 
exclude an interference of mRNA derived from blood 
cells. 
Investigation of defined cell types of the immune sys- 
tem revealed that three of the four known human PDE 
IV genes display differential expression patterns in vari- 
ous cell types of the immune system, while one isoform 
(hPDE IV-C) is lacking completely in this system. The 
distinct isozyme expression in eosinophils, neutrophils 
and T-cells (all of which are involved in inflammatory 
reactions) suggests that the isozymes may modulate dif- 
ferent pools of intracellular cAMP which are important 
for the particular esponses of these cells. A differential 
expression of cAMP-PDEs was also described for the rat 
testis [9,10] where rPDE IV-A and -C are expressed in 
germ cells whereas rPDE IV-B and -D were found in 
somatic cells. Furthermore, in rat brain distinct expres- 
sion patterns of the four isogenes were shown by in situ 
hybridization with overlapping expression in hippocam- 
pus and cerebellum but differences in midbrain and cor- 
tex [26]. In human neuronal tissue it was demonstrated 
that no expression of hPDE IV-C occurred in temporal 
cortex and glioblastoma cells whereas in SH-N-SK neu- 
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roblastoma cells this isoform was detected in RNAse- 
protection experiments [6]. It seems clear from our data, 
however, that individual cell types can express everal or 
all PDE IV isoforms. To explain the benefit for the cell 
of the expression of the multiple isoforms, it needs to be 
discovered whether functional or regulatory differences 
between these isoforms exist or whether they are present 
in different subcellular compartments. In this respect it 
is interesting to note that rPDE IV-A (RD 1) was found 
as a membrane-bound isoform [27,28] whereas rPDE 
IV-D was found in soluble fractions of stimulated Sertoli 
cells by other authors [13,20]. 
Our comparison of the human and rat tissue distribu- 
tion revealed significant differences between the two spe- 
cies. It must be assumed that either species-specific dif- 
ferences in expression patterns exist indeed or that the 
correlation between the cloned human and rat PDE IV 
isogenes is partly incorrect. The existence of additional, 
as yet unidentified, PDE IV isogenes would then have to 
be postulated. 
Further experiments were performed to investigate the 
regulation of the hPDE IV isogenes in different human 
cell types. It has recently been demonstrated that cAMP 
phosphodiesterase activity can be increased by cAMP 
via protein kinase A in myoblasts [29]. PDE IV activity 
was further found to be elevated in FRTL-5 cells after 
treatment with thyroid-stimulating hormone (TSH), a 
process which is mediated by cAMP-dependent phos- 
phorylation [22]. Other authors describe the induction of 
PDE IV gene expression in Sertoli or C6-glioblastoma 
cells after treatment of the cells with dbcAMP, forskolin 
or FSH [20,23,30] where correlation between elevated 
mRNA levels and protein activity was demonstrated. 
Therefore, cAMP may mediate PDE activity both via 
protein modification and induction of transcription. 
Our experiments in human cells showed that expres- 
sion of three of the four human isogenes can be induced 
in cells derived from the immune system but not in a 
neuronal cell line. This is particularly important if a 
long-term treatment of patients with PDE IV inhibitors 
is envisaged, which has been proposed for various dis- 
eases, cAMP-dependent upregulation of PDEs may out- 
balance the effects of PDE inhibitors in certain tissues. 
Our data suggest hat distinct regulatory mechanisms 
exist in different cell types. Modulation of cAMP levels 
may be achieved by differential regulation of expression 
of PDE IV isozymes. Second messenger-dependent r gu- 
lation of PDE gene expression has also been found for 
other PDE subfamilies. For instance, expression of Ca2+/ 
Calmodulin dependent phosphodiesterases is increased 
by Calmodulin or by cAMP-dependent protein kinase 
phosphorylation [31]. Other authors described the regu- 
lation of nucleotide phosphodiesterases in liver by glu- 
cagon and insulin [32]. 
In conclusion, our results suggest hat the PDE IV 
subtypes fulfil different roles in the regulation of cellular 
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cAMP-dependent  processes. Ind iv idua l  cells may con-  
ta in one or  several PDE IV subtypes which may occur 
in different intracel lu lar  local izat ions. The specific pat-  
terns o f  PDE IV subtype expression and the differences 
in their t ranscr ipt iona l  regulat ion may enable the cells to 
var iably  regulate cAMP-degradat ion  in dif ferent cel lular 
compar tments .  
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